Last reviewed · How we verify
NCT04222231: RESIST
RESIST! Blood-flow Restriction Resistance Training for Improving Insulin Sensitivity in Type 2 Diabetes
NA trial testing Blood-flow restriction resistance training in Type 2 Diabetes in 24 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | German Diabetes Center |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 24 |
| Start date | 28 October 2019 |
| Primary completion | 31 December 2023 |
| Estimated completion | 1 March 2024 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Blood-flow restriction resistance training
- Classical resistance training
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
German Diabetes Center — full company profile →
Who can join
Adults 30 to 69, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to investigate the metabolic and cardiovascular effects of classical resistance training with high loads and blood-flow restricted training (BFRT) with low loads in individuals with type 2 diabetes over 12 weeks.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Blood-flow restriction resistance training improves skeletal muscle mitochondrial capacity and cardiovascular risk factors in type 2 diabetes.
Trinks N, Gancheva S, Pützer J, Schön M, et al · · 2026 · PMID 41610852 · DOI 10.1016/j.cmet.2025.12.016
Verify or expand the search:
- PubMed search for NCT04222231
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other German Diabetes Center trials
Trials by the same sponsor.
- NCT06193668 — Overfeeding Induced Fat-tissue Stimulation · NA · recruiting
- NCT04219215 — Acute Hyperbaric Oxygen Treatment Increases Hepatic Insulin Sensitivity and Muscle Reactive Oxygen Species in T2D · NA · completed
- NCT04088851 — "Hepatic Substrate Flux Rates in Type 2 Diabetes" · NA · active not recruiting
- NCT05046483 — Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI · recruiting
- NCT04509245 — The Effects of a Novel Lifestyle Intervention Program on Insulin Sensitivity in Type 2 Diabetes · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04222231 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by German Diabetes Center
- Last refreshed: 13 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04222231.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing